NextCure & LCB Present Promising B7-H4 ADC Data at AACR 2024
NextCure, Inc. and LigaChem Biosciences are gearing up to present new preclinical data on their novel cancer therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025.
LNCB74: A Novel Cancer Therapy
LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients with advanced solid tumors. These include platinum-resistant ovarian, treatment-refractory breast, endometrial, biliary tract, and squamous non-small cell lung cancers.
Phase 1 Trial Details
The ongoing Phase 1 study is in the dose escalation phase and will also include randomized dose expansion and optimization, with an emphasis on safety and biomarker analysis. B7-H4, the ADC’s target, is highly expressed in several tumor types but limited in normal tissues, making it an appealing candidate for targeted therapy.
Preclinical Results
According to NextCure, Inc.’s Chief Medical Officer, Dr. Udayan Guha, LNCB74 has shown a superior safety profile and potent anti-tumor activity in preclinical models. The poster, abstract TPS3167, will be featured during the “Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology” session.
